NASDAQ:NK NantKwest (NK) Stock Price, News & Analysis → Urgent Nvidia Warning (From Altimetry) (Ad) Free NK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$7.45▼$8.9950-Day Range$16.09▼$38.7052-Week Range$2.52▼$45.42Volume12.80 million shsAverage Volume1.57 million shsMarket Capitalization$933.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get NantKwest alerts: Email Address Ad Stansberry Research$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).Find out how to do right here in this free video. About NantKwest Stock (NASDAQ:NK)NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.Read More Ad Stansberry Research$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).Find out how to do right here in this free video. NK Stock News HeadlinesFebruary 4, 2024 | time.comSpace Nk Promo CodesAugust 13, 2023 | mirror.co.ukFrankie Bridge shares her new Space NK beauty buys including concealer people 'love'May 2, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.May 13, 2023 | msn.comPiper Sandler Downgrades ImmunityBio (IBRX)May 12, 2023 | investing.comNantKwest Inc (IBRX) Earnings Dates & ReportsMay 10, 2023 | marketwatch.comNK Cells Market Report | Research Across The World 2031March 9, 2023 | marketwatch.comNatural Killer Cell Therapy Market Size, Growth | Soaring Demand | 2023 - 2029January 12, 2023 | marketwatch.comNatural Killer Cell Therapy Market 2023 Statistics, Share Price, Growth Prospects, Industry Trends till 2028May 2, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.November 26, 2022 | marketwatch.comNK Cell Therapy Market Insights: Industry changing aspects, New Technologies and Forecast to 2025 | Market Growth ReportsSeptember 29, 2022 | marketwatch.comNatural Killer Cells Therapeutics Market 2022 : Top Manufacturers, Key Trends, Progression Status and Business Trends to 2027August 22, 2022 | marketwatch.comNatural Killer Cell Therapy Market 2022 Production, Revenue, Growth Rate, Price and Gross Margin, Opportunities and Forecast 2026August 12, 2022 | finance.yahoo.comGlobal Engineered T Cells Market Report 2022-2027: Immuno-Oncology Sector Increasing R&D Funding & Expanding Gene Therapy Marketspace Generating High-Potential Opportunities - Yahoo FinanceAugust 11, 2022 | benzinga.comGlobal Engineered T Cells Market Report 2022-2027: Increasing Demand for Innovative Biopharmaceutical The - BenzingaJuly 6, 2022 | finance.yahoo.comHarpoon Therapeutics Expands Leadership Team - Yahoo FinanceJune 18, 2022 | streetinsider.comCelldex (CLDX) Appoints Cheryl L. Cohen and Dr. Garry Neil to its Board - StreetInsider.comJune 16, 2022 | finance.yahoo.comCelldex Announces Two New Appointments to its Board of Directors - Yahoo FinanceMay 13, 2022 | prnewswire.comImmPACT Bio Names Sylvain Roy as Chief Technology Officer - PR NewswireMay 4, 2022 | finance.yahoo.comRAPT Therapeutics Expands Leadership Team with Multiple Key Hires - Yahoo FinanceMay 4, 2022 | marketscreener.comRAPT Therapeutics Expands Leadership Team with Multiple Key Hires - Marketscreener.comMarch 29, 2022 | businessinsider.comList: the 17 Fastest-Growing Biotechs and Pharmas of 2021 - Business InsiderMarch 10, 2022 | businesswire.comNatural Killer (NK) Cell Therapy Market Research Report 2022 - Comprehensive Insights about 100+ Companies and 185+ Pipeline Drugs - ResearchAndMarkets.com - Business WireFebruary 10, 2022 | ft.comBiotechs face cash crunch after stock market ‘bloodbath’ - Financial TimesJanuary 29, 2022 | businesswire.comBladder Cancer Disease Market Analysis Research Report 2021 - ResearchAndMarkets.com - Business WireDecember 20, 2021 | finance.yahoo.comImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing - Yahoo FinanceOctober 29, 2021 | businesswire.comAmbrx Biopharma Inc. Reports 1H 2021 Financial Results and Provides Corporate Update - Business WireOctober 20, 2021 | businesswire.comGlobal Natural Killer Cell Therapies Pipeline Insight Report 2021: 100+ Companies and 140+ Pipeline Drugs - ResearchAndMarkets.com - Business WireSee More Headlines Receive NK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NantKwest and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/11/2020Today5/02/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:NK CUSIPN/A CIK1326110 Webwww.nantkwest.com Phone858-633-0300FaxN/AEmployees160Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,790,000.00 Net Margins-76,658.58% Pretax MarginN/A Return on Equity-56.06% Return on Assets-46.93% Debt Debt-to-Equity RatioN/A Current Ratio4.74 Quick Ratio4.74 Sales & Book Value Annual Sales$40,000.00 Price / Sales23,345.16 Cash FlowN/A Price / Cash FlowN/A Book Value$1.23 per share Price / Book6.94Miscellaneous Outstanding Shares109,345,000Free FloatN/AMarket Cap$933.81 million OptionableNot Optionable Beta2.61 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Barry J. Simon (Age 56)Pres, Chief Admin. Officer & Exec. Director Comp: $454.44kMs. Sonja Nelson (Age 48)Chief Financial Officer Comp: $442.69kMr. Richard Gerald Adcock (Age 52)Chief Exec. Officer Mr. Steven Yang J.D.VP, Gen. Counsel & Corp. Sec.Dr. Jerel A. Banks Ph.D. (Age 46)M.D., Sr. VP Mergers and Acquisitions Mr. Leonard S. SenderSr. VP of Medical Affairs - Pediatric, Adolescent & Young Adult OncologyDr. Hans Georg Klingemann (Age 71)VP of R&D More ExecutivesKey CompetitorsRelay TherapeuticsNASDAQ:RLAYBioCryst PharmaceuticalsNASDAQ:BCRXImmaticsNASDAQ:IMTXAutolus TherapeuticsNASDAQ:AUTLMesoblastNASDAQ:MESOView All Competitors NK Stock Analysis - Frequently Asked Questions How were NantKwest's earnings last quarter? NantKwest, Inc. (NASDAQ:NK) announced its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.02. The biotechnology company earned $0.02 million during the quarter. NantKwest had a negative net margin of 76,658.58% and a negative trailing twelve-month return on equity of 56.06%. What is Dr. Patrick Soon-Shiong's approval rating as NantKwest's CEO? 14 employees have rated NantKwest Chief Executive Officer Dr. Patrick Soon-Shiong on Glassdoor.com. Dr. Patrick Soon-Shiong has an approval rating of 55% among the company's employees. This puts Dr. Patrick Soon-Shiong in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of NantKwest own? Based on aggregate information from My MarketBeat watchlists, some companies that other NantKwest investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN) and ADMA Biologics (ADMA). When did NantKwest IPO? NantKwest (NK) raised $150 million in an initial public offering (IPO) on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager. This page (NASDAQ:NK) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsTruth about Trump you’ve never heardPorter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithAI “wealth window” is closing June 25thParadigm Press4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NantKwest, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.